Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma
Abstract
Background Immunotherapy using autologous dendritic cell (DC) vaccination has not been systematically evaluated in osteosarcoma. We therefore conducted a phase I trial to assess feasibility, safety and tumour-specific immune responses in patients with relapsed disease. Patients and methods Of 13 recruited patients with relapsed osteosarcoma, 12 received 3 weekly vaccines of autologous DCs matured with autologous tumour lysate and keyhole limpet haemocyanin (KLH), to a maximum of 6 vaccinations. An additional 3 paediatric patients afflicted with other tumour types and with relapsed disease received vaccines generated with identical methodology. Immune responses were assessed using an ELISpot assay for the detection of interferon gamma, whilst interleukin-2 and granzyme B were additionally assessed in cases where interferon-γ responses were induced. Results In total 61 vaccines, of homogeneous maturation phenotype and viability, were administered with no significant toxicity. Only in 2 out of 12 treated osteosarcoma cases was there an induction of specific T-cell immune response to the tumour, whilst a strong but non-specific immune response was induced in 1 further osteosarcoma patient. Immune response against KLH was induced in only 3 out of 12 osteosarcoma patients. In contrast, three additional non-osteosarcoma patients showed significant T-cell responses to vaccine. Conclusion We have shown the strategy of DC vaccination in relapsed osteosarcoma is safe and feasible. However, significant anti-tumour responses were induced in only 2 out of 12 vaccinated patients with no evidence of clinical benefit. Comparison of results with identically treated control patients suggests that osteosarcoma patients might be relatively insensitive to DC-based vaccine treatments.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In clinical trials, DC vaccines showed limited effect for the treatment of osteosarcoma.
“However, in clinical trials, DC vaccines showed limited effect for the treatment of osteosarcoma [65, 66].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [65]
Cites
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862 · see citing works
Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., Driesch, P. V. D., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1669 · Cited by 1,226 · see citing works
Prostaglandins as modulators of immunity
Harris, S. G., Padilla, J., Koumas, L., Ray, D. M., & Phipps, R. P. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02154-8 · Cited by 1,168 · see citing works
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · see citing works
Geiger, J. D., Hutchinson, R. J., Hohenkirk, L., McKenna, E. A., Yanik, G. A., Levine, J. E., Chang, A. E., Braun, T., & Mulé, J. J. (2001) · PubMed · Cited by 320 · see citing works
Bérard, F., Blanco, P., Davoust, J. M., Neidhart-Berard, E.-M., Nouri-Shirazi, M. A., Taquet, N., Rimoldi, D., Cerottini, J.-C., Banchereau, J., & Palucka, K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.11.1535 · Cited by 283 · see citing works
Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion
Chizzolini, C., Chicheportiche, R., Alvarez, M., de Rham, C., Roux‐Lombard, P., Ferrari‐Lacraz, S., & Dayer, J. (2008) · Blood · doi:10.1182/blood-2008-05-155408 · Cited by 235 · see citing works
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Ribas, A., Comı́n-Anduix, B., Chmielowski, B., Jalil, J., de la Rocha, P., McCannel, T. A., Ochoa, M. T., Seja, E., Villanueva, A., Oseguera, D. K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1254 · Cited by 217 · see citing works
Caruso, D. A., Orme, L. M., Neale, A. M., Radcliff, F. J., Amor, G. M., Maixner, W., Downie, P., Hassall, T. E., Tang, M. L. K., & Ashley, D. M. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000668 · Cited by 165 · see citing works
Napolitani, G., Rodríguez, E. V. A., Lanzavecchia, A., & Sallusto, F. (2009) · European Journal of Immunology · doi:10.1002/eji.200838969 · Cited by 146 · see citing works
Adjuvant dendritic cell‐based tumour vaccination for children with malignant brain tumours
Ardon, H., Vleeschouwer, S. D., Calenbergh, F. V., Claes, L., Kramm, C. M., Rutkowski, S., Wolff, J. E. A., & Gool, S. W. V. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22319 · Cited by 144 · see citing works
Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells
Geiger, J. D., Hutchinson, R. J., Hohenkirk, L., McKenna, E., Chang, A. E., & Mulé, J. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02762-8 · Cited by 103 · see citing works
Dohnal, A. M., Witt, V., Hügel, H., Holter, W., Gadner, H., & Felzmann, T. (2007) · Cytotherapy · doi:10.1080/14653240701589221 · Cited by 78 · see citing works
Therapeutic Dendritic Cell Vaccination of Patients with Renal Cell Carcinoma
Berntsen, A., Geertsen, P. F., & Svane, I. M. (2006) · European Urology · doi:10.1016/j.eururo.2006.03.061 · Cited by 56 · see citing works
Rubio, M., Means, T. K., Chakraverty, R. K., Shaffer, J., Fudaba, Y., Chittenden, M., Luster, A. D., & Sykes, M. (2005) · International Immunology · doi:10.1093/intimm/dxh335 · Cited by 51 · see citing works
Suminoe, A., Matsuzaki, A., Hattori, H., Koga, Y., & Hara, T. (2008) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2008.01066.x · Cited by 49 · see citing works
Brown, M. D., Zhang, Y., Dermine, S., de Wynter, E. A., Hart, C. A., Kitchener, H. C., Stern, P. L., Skinner, M. A., & Stacey, S. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301288 · Cited by 42 · see citing works
Matsuzaki, A., Suminoe, A., Hattori, H., Hoshina, T., & Hara, T. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200203000-00012 · Cited by 39 · see citing works
Shilyansky, J., Jacobs, P., Doffek, K. M., & Sugg, S. L. (2007) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2006.09.008 · Cited by 14 · see citing works
Palmerini, E., Staals, E. L., Ferrari, S., Rinaldi, R., Alberghini, M., Mercuri, M., & Bacci, G. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.g.01619 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294 · see citing works
Antitumour dendritic cell vaccination in a priming and boosting approach
Harari, A., Graciotti, M., Bassani‐Sternberg, M., & Kandalaft, L. E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0074-8 · Cited by 271 · see citing works
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270 · see citing works
“However, in clinical trials, DC vaccines showed limited effect for the treatment of osteosarcoma [65, 66].”
BackgroundKoirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267 · see citing works
Osteosarcoma: A comprehensive review of management and treatment strategies
Jafari, F., Javdansirat, S., Sanaie, S., Naseri, A., Shamekh, A., Rostamzadeh, D., & Dolati, S. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151654 · Cited by 253 · see citing works
Vacchelli, E., Vitale, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Cremer, I., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 246 · see citing works
Genetically engineered T cells for cancer immunotherapy
Li, D., Li, X., Zhou, W.-L., Huang, Y., Liang, X., Jiang, L., Yang, X., Sun, J., Li, Z., Han, W., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0070-9 · Cited by 245 · see citing works
Wang, L., Zhang, Q., Chen, W., Shan, B., Ding, Y., Zhang, G., Cao, N., Liu, L., & Zhang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070689 · Cited by 177 · see citing works
Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind, M. F., Wagner, L. M., & Cripe, T. P. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27227 · Cited by 153 · see citing works
Current and Emerging Targets in Immunotherapy for Osteosarcoma
Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · Journal of Oncology · doi:10.1155/2019/7035045 · Cited by 123 · see citing works
Zhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000474 · Cited by 112 · see citing works
Miwa, S., Nishida, H., Tanzawa, Y., Takeuchi, A., Hayashi, K., Yamamoto, N., Mizukoshi, E., Nakamoto, Y., Kaneko, S., & Tsuchiya, H. (2017) · Cancer · doi:10.1002/cncr.30606 · Cited by 95 · see citing works
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90 · see citing works
Emerging trends in immunotherapy for pediatric sarcomas
Dyson, K. A., Stover, B. D., Grippin, A., Méndez‐Gómez, H. R., Lagmay, J., Mitchell, D. A., & Sayour, E. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0756-z · Cited by 88 · see citing works
Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma
Wang, Z., Wang, Z., Li, B., Wang, S., Chen, T., & Ye, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01114 · Cited by 76 · see citing works
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73 · see citing works
Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies
Ji, Z., Shen, J., Lan, Y., Yi, Q., & Liu, H. (2023) · MedComm · doi:10.1002/mco2.308 · Cited by 68 · see citing works
Osteosarcoma: Current Concepts and Evolutions in Management Principles
Pilavaki, P., Ardakani, A. H. G., Gikas, P. D., & Constantinidou, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082785 · Cited by 70 · see citing works
Therapeutic Targets for Bone and Soft-Tissue Sarcomas
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010170 · Cited by 65 · see citing works
Drugs in early clinical development for the treatment of osteosarcoma
Heymann, M., Brown, H. K., & Heymann, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1237503 · Cited by 62 · see citing works
Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas
Nathenson, M. J., Conley, A. P., & Sausville, E. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0025 · Cited by 61 · see citing works
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1
Ferris, S. T., Ohara, R. A., Ou, F., Wu, R., Huang, X., Kim, S. K., Chen, J., Liu, T., Schreiber, R. D., Murphy, T. L., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0865 · Cited by 60 · see citing works
Bone sarcomas in the immunotherapy era
Heymann, M., Schiavone, K., & Heymann, D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14999 · Cited by 57 · see citing works
Immunotherapeutic Approaches to Sarcoma
Burgess, M. A., & Tawbi, H. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0345-5 · Cited by 55 · see citing works
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 55 · see citing works
A Review of Dendritic Cell Therapy for Cancer: Progress and Challenges
Mantia-Smaldone, G. M., & Chu, C. (2013) · BioDrugs · doi:10.1007/s40259-013-0030-9 · Cited by 40 · see citing works
Olsen, H. E., Lynn, G. M., Valdes, P. A., Cerecedo-Lopez, C. D., Ishizuka, A. S., Arnaout, O. M., Bi, W. L., Peruzzi, P. P., Chiocca, E. A., Friedman, G. K., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab027 · Cited by 35 · see citing works
Dendritic cell vaccines: A review of recent developments and their potential pediatric application
Elster, J. D., Krishnadas, D. K., & Lucas, K. G. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1179844 · Cited by 34 · see citing works
Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma
Yan, P., Wang, J., Yue, B., & Wang, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189171 · Cited by 31 · see citing works
Advances and challenges in the treatment of osteosarcoma
Wang, X., Zhu, K., Hu, J., & Zhang, C. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.07.001 · Cited by 31 · see citing works
The future of immunotherapy for sarcoma
Tsukahara, T., Emori, M., Murata, K., Mizushima, E., Shibayama, Y., Kubo, T., Kanaseki, T., Hirohashi, Y., Yamashita, T., Sato, N., et al. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1188075 · Cited by 29 · see citing works
Immune checkpoint inhibitors in sarcomas: a systematic review
Anastasiou, Μ., Kyriazoglou, A. I., Kotsantis, I., Economopoulou, P., Kyrkasiadou, M., Giannopoulou, A. E., Kosmidou, A., Smerdi, D., Moutafi, M. K., Gavrielatou, N., et al. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100407 · Cited by 24 · see citing works
Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors
Wijfjes, Z., van Dalen, F. J., Gall, C. M. L., & Verdoes, M. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00330 · Cited by 22 · see citing works
Bozorgi, A., & Sabouri, L. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100324 · Cited by 22 · see citing works
Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
de Bruijn, S., Anguille, S., Verlooy, J., Smits, E., Tendeloo, V. F. V., Laere, M. D., Norga, K., Berneman, Z. N., & Lion, E. (2019) · Cancers · doi:10.3390/cancers11091396 · Cited by 22 · see citing works
Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development
Gautam, N., Ramamoorthi, G., Champion, N., Han, H. S., & Czerniecki, B. J. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101239 · Cited by 19 · see citing works
Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights
Zhang, Y., Jiang, S., Lv, J., Feng, W., Yu, Y., & Zhao, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584450 · Cited by 22 · see citing works
Exploring the landscape of immunotherapy approaches in sarcomas
Pilavaki, P., Panagi, M., Arifi, S., Jones, R. L., Stylianopoulos, T., & Constantinidou, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1069963 · Cited by 17 · see citing works
Sarcoma Tumor Microenvironment
Tsagozis, P., Gonzalez‐Molina, J., Georgoudaki, A., Lehti, K., Carlson, J. W., Lundqvist, A., Haglund, F., & Ehnman, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_20 · Cited by 17 · see citing works
Current Status of Immunotherapy for Sarcomas
Miwa, S., Nishida, H., & Tsuchiya, H. (2017) · Immunotherapy · doi:10.2217/imt-2017-0101 · Cited by 16 · see citing works
Benteyn, D., Nuffel, A. M. T. V., Wilgenhof, S., & Bonehill, A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0345-0_1 · Cited by 16 · see citing works
Role of immunotherapy in chondrosarcoma: A case report and review of the literature
Cohen-Nowak, A. J., Dressler, D. B., Rock, A., Mojica, K., Woo, D., Zuckerman, L. M., Chow, W., & Agulnik, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231199877 · Cited by 16 · see citing works
A Review of T-Cell Related Therapy for Osteosarcoma
Yoshida, K., Okamoto, M., Aoki, K., Takahashi, J., & Saito, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144877 · Cited by 14 · see citing works
Adoptive Cell Therapy for Sarcoma
Mata, M., & Gottschalk, S. M. (2015) · Immunotherapy · doi:10.2217/imt.14.98 · Cited by 13 · see citing works
CD103+ cDC1 Dendritic Cell Vaccine Therapy for Osteosarcoma Lung Metastases
Yang, Y., Zhou, Y., Wang, J., Zhou, Y. L., Watowich, S. S., & Kleinerman, E. S. (2024) · Cancers · doi:10.3390/cancers16193251 · Cited by 12 · see citing works
Immunotherapy for Neuroblastoma
Kudva, A., & Modak, S. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812005-7.00009-6 · Cited by 12 · see citing works
Optimization of methodology for production of CD25/CD71 allodepleted donor T cells for clinical use
Albon, S. J., Mancao, C., Gilmour, K. C., White, G., Ricciardelli, I., Brewin, J., Lugthart, G., Wallace, R., & Amrolia, P. J. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2012.10.007 · Cited by 11 · see citing works
Self-citationSun, C., MA, X., ZHOU, C., Zhang, Z., & GUO, J. (2023) · Anticancer Research · doi:10.21873/anticanres.16514 · Cited by 10 · see citing works
Markov, O. V., Mironova, N. L., Vlassov, V. V., & Аркадьевна, З. М. (2017) · Acta Naturae · doi:10.32607/20758251-2017-9-3-27-38 · Cited by 10 · see citing works
Liu, G., Xiaoyan, F., Cai, Y., Fu, Z., Gao, F., Dong, J., Li, K., & Cai, J. (2019) · Immunotherapy · doi:10.2217/imt-2018-0103 · Cited by 9 · see citing works
Immune-based prognostic biomarkers associated with metastasis of osteosarcoma
Ma, T., Peng, C., Wu, D., Yang, S., Li, J., Zhang, C., & Gao, C. (2023) · General Physiology and Biophysics · doi:10.4149/gpb_2022050 · Cited by 8 · see citing works
Gao, M., Liu, W., Li, T., Song, Z., Wang, X., & Zhang, X. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10497-4 · Cited by 8 · see citing works
Immune Environment and Osteosarcoma
Heymann, M., & Heymann, D. (2017) · InTech eBooks · doi:10.5772/67448 · Cited by 8 · see citing works
Dai, Z., Liu, Z., Yang, R., Cao, W., & Ji, T. (2023) · Biomolecules · doi:10.3390/biom13020327 · Cited by 7 · see citing works
Chew, H. Y., Chan, V., Simpson, F., & Dolcetti, R. (2020) · Cancers · doi:10.3390/cancers12113392 · Cited by 6 · see citing works
Novel anthracyclines with enhanced immunogenic effects against drug resistant osteosarcoma cells
Gazzano, E., Kopecka, J., Castella, B., Buondonno, I., Costamagna, C., & Riganti, C. (2018) · Journal of Molecular and Clinical Medicine · doi:10.31083/j.jmcm.2018.04.325001 · Cited by 4 · see citing works
Li, Y., Wang, D., & Fang, X. (2019) · Fetal and Pediatric Pathology · doi:10.1080/15513815.2019.1600624 · Cited by 4 · see citing works
Zuo, S., Cheng, N., Hou, Z., Yang, Y., Tian, Q., & Yisheng, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1865742 · Cited by 3 · see citing works
Breaking down the tumor immune infiltration within pediatric sarcomas
Weil, R., & Loeb, D. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1187289 · Cited by 3 · see citing works
Overall review of curative impact and barriers of CAR-T cells in osteosarcoma
Li, G., Wang, H., & Meftahpour, V. (2023) · EXCLI journal · doi:10.17179/excli2023-6760 · Cited by 4 · see citing works
Miwa, S., Nojima, T., Alomesen, A., Ikeda, H., Yamamoto, N., Nishida, H., Hayashi, K., Takeuchi, A., Igarashi, K., Higuchi, T., et al. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02559-z · Cited by 3 · see citing works
Mo, C., Xie, L., Chen, C., Ma, J., Huang, Y., Wu, Y. X., Xu, Y., Peng, H., Chen, Z., & Mao, R. (2021) · Journal of Oncology · doi:10.1155/2021/7228584 · Cited by 3 · see citing works
Applications of intelligent biomaterials in cancer immunotherapy: A review
Katiyar, D. (2023) · Materials Today Proceedings · doi:10.1016/j.matpr.2023.05.460 · Cited by 3 · see citing works
Advances in T cell–based immunotherapy for osteosarcoma
Zhang, K., Wang, Z., He, J., Lu, L., Wang, W., Yang, A., Xie, H., Huang, L., Huang, Y., Zhang, K., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769847 · Cited by 3 · see citing works
Li, H., Liu, C., Zhang, B., Zhang, Y., & Liu, Y. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06471-3 · Cited by 2 · see citing works
Sorteberg, A. L., Ek, L., Lilienthal, I., & Herold, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_236-1 · Cited by 2 · see citing works
Nakajima, M., & Modak, S. I. (2017) · Springer eBooks · doi:10.1007/978-3-319-43486-5_10 · Cited by 2 · see citing works
Sorteberg, A. L., Ek, L., Lilienthal, I., & Herold, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_236 · Cited by 1 · see citing works
The immune environment of bone sarcomas
Richert, I., & Dutour, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00070-0 · Cited by 1 · see citing works
Novel Therapies on the Horizon
Cripe, T. P., Haworth, K. B., & Houghton, P. J. (2015) · Pediatric oncology · doi:10.1007/978-3-319-18099-1_15
Enhancing Cancer Immunotherapies Using Cell-Based or Viral Vectored Vaccines
Mould, R. C. (2020) · The Atrium (University of Guelph)
Feeder-free generation of functional dendritic cells from human pluripotent stem cells
Jung, W., Khalil, A. S., Binenbaum, Y., Price, J. M. J., Vining, K. H., Lungjangwa, T., Sobral, M. C., Jaenisch, R., & Mooney, D. J. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014402
Shi, J., & Chen, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1919497
- Authors
- Himoudi, N., Wallace, R., Parsley, K. L., Gilmour, K., Barrie, A.-U., Howe, K., Dong, R., Sebire, N. J., Michalski, A., Thrasher, A. J., & Anderson, J.
- Affiliations
- University College London (GB)
- Great Ormond Street Hospital (GB)
- Corresponding author
- Anderson, John
- ORCID
- Venue
- Clinical and Translational Oncology
- Published
- 2012-04
- Volume
- 14
- Issue
- 4
- Pages
- 271-279
- ISSN
- 1699-048X (ISSN-L)
- 1699-3055
- OpenAlex
- W2050553762
- Cited by
- 74
- References
- 20
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 3 · 2023: 15 · 2022: 3 · 2021: 5 · 2020: 9 · 2019: 9 · 2018: 2 · 2017: 6 · 2016: 5 · 2015: 3 · 2014: 2 · 2013: 4
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Clinical & Translational Oncology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust (090233)
- Cancer Research UK (C7262/A7910)
- National Institute for Health and Care Research (NF-SI-0611-10001)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- dendritic cell vaccination, osteosarcoma, relapsed osteosarcoma, keyhole limpet hemocyanin, interferon-gamma, tumor immunogenicity, childhood cancer
- MeSH terms
- Adolescent, Adult, Dendritic Cells, Feasibility Studies, Female, Hemocyanins, Humans, Immunotherapy, Interferon-gamma, Interleukin-2, Male, Phenotype, Recurrence, Osteosarcoma, T-Lymphocytes, Treatment Outcome, Cancer Vaccines, Granzymes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
